Kingchem (Liaoning) Life Science Valuation

Is 301509 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301509 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301509 (CN¥28.77) is trading above our estimate of fair value (CN¥5.12)

Significantly Below Fair Value: 301509 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301509?

Key metric: As 301509 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301509. This is calculated by dividing 301509's market cap by their current earnings.
What is 301509's PE Ratio?
PE Ratio	52x
Earnings	CN¥66.66m
Market Cap	CN¥3.47b

301509 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.9x
Enterprise Value/EBITDA	20.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 301509's PE Ratio compare to its peers?

The above table shows the PE ratio for 301509 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	63.2x
002688 Jinhe Biotechnology	35.7x	n/a	CN¥3.6b
002923 Zhuhai Rundu Pharmaceutical	92x	n/a	CN¥3.5b
600613 Shanghai Shenqi Pharmaceutical Investment Management	77.8x	n/a	CN¥3.8b
301201 ChengDa Pharmaceuticals	47.3x	n/a	CN¥3.4b
301509 Kingchem (Liaoning) Life Science	52x	n/a	CN¥3.5b

Price-To-Earnings vs Peers: 301509 is good value based on its Price-To-Earnings Ratio (52x) compared to the peer average (64.1x).

Price to Earnings Ratio vs Industry

How does 301509's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 301509 is expensive based on its Price-To-Earnings Ratio (52x) compared to the CN Pharmaceuticals industry average (32.9x).

Price to Earnings Ratio vs Fair Ratio

What is 301509's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301509 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	52x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301509's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.